



# Hydroxylation and dechlorination of 3,3',4,4'-tetrachlorobiphenyl (CB77) by rat and human CYP1A1s and critical roles of amino acids composing their substrate-binding cavity

Yabu, Miku ; Haga, Yuki ; Itoh, Toshimasa ; Goto, Erika ; Suzuki, Motoharu ; Yamazaki, Kiyoshi ; Mise, Shintaro ; Yamamoto, Keiko ;...

---

(Citation)

Science of the Total Environment, 837:155848

(Issue Date)

2022-09-01

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2022 Elsevier B.V.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license

<http://creativecommons.org/licenses/by-nc-nd/4.0/>

(URL)

<https://hdl.handle.net/20.500.14094/90009329>



***Hydroxylation and dechlorination of 3,3',4,4'-tetrachlorobiphenyl (CB77) by rat and human CYP1A1s and critical roles of amino acids composing their substrate-binding cavity***

*Miku Yabu<sup>a</sup>, Yuki Haga<sup>b</sup>, Toshimasa Itoh<sup>c</sup>, Erika Goto<sup>a</sup>, Motoharu Suzuki<sup>b</sup>, Kiyoshi Yamazaki<sup>a</sup>, Shintaro Mise<sup>a</sup>, Keiko Yamamoto<sup>c</sup>, Chisato Matsumura<sup>b</sup>, Takeshi Nakano<sup>d</sup>, Toshiyuki Sakaki<sup>e</sup>, and Hideyuki Inui<sup>a,f,\*</sup>*

<sup>a</sup> Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodaicho, Nada-ku, Kobe, Hyogo 657-8501, Japan

<sup>b</sup> Hyogo Prefectural Institute of Environmental Sciences, 3-1-18 Yukihirocho, Suma-ku, Kobe, Hyogo 654-0037, Japan

<sup>c</sup> Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan

<sup>d</sup> Research Center for Environmental Preservation, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan

<sup>e</sup> Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398

<sup>f</sup> Biosignal Research Center, Kobe University, 1-1 Rokkodaicho, Nada-ku, Kobe, Hyogo 657-8501, Japan

\*Corresponding Author

Hideyuki Inui, Biosignal Research Center, Kobe University, 1-1 Rokkodaicho, Nada-ku, Kobe, Hyogo, 657-8501, Japan

E-mail: [hinui@kobe-u.ac.jp](mailto:hinui@kobe-u.ac.jp), Telephone number: +81-78-803-5863

## ABSTRACT

Cytochrome P450 (CYP) monooxygenases play critical roles in determining the toxicity of polychlorinated biphenyls (PCBs) in mammals. Hydroxylation of PCBs by these enzymes leads to increased water solubility, promoting the elimination of PCBs from the body. The CYP1 family is mainly responsible for metabolizing PCBs that exhibit a dioxin-like toxicity. Although the dioxin-like PCB 3,3',4,4'-tetrachlorobiphenyl (CB77) is abundant in the environment and accumulates in organisms, information on CB77 metabolism by CYP1A1s is limited. In this study, recombinant rat CYP1A1 metabolized CB77 to 4'-hydroxy (OH)-3,3',4,5'-tetrachlorobiphenyl (CB79) and 4'-OH-3,3',4-trichlorobiphenyl (CB35), whereas human CYP1A1 produced only 4'-OH-CB79. Rat CYP1A1 exhibited much higher metabolizing activity than human CYP1A1 because CB77 was stably accommodated in the substrate-binding cavity of rat CYP1A1 and was close to its heme. In a rat CYP1A1 mutant with two human-type amino acids, the production of 4'-OH-CB79 decreased, whereas that of the dechlorinated metabolite 4'-OH-CB35 increased. These results are explained by a shift in the CB77 positions toward the heme. This study provides insight into the development of enzymes with high metabolizing activity and clarifies the structural basis of PCB metabolism, as dechlorination contributes to a drastic decrease in dioxin-like toxicity.

KEYWORDS: cytochrome P450 monooxygenase, dechlorination, dioxin-like polychlorinated biphenyl, docking model, hydroxylation, 3,3',4,4'-tetrachlorobiphenyl

## 1. Introduction

Cytochrome P450 (P450 or CYP) monooxygenases are heme proteins widely distributed in microorganisms, plants, and animals. They play an important role in the oxidative reactions involved in the biosynthesis of endogenous compounds and the xenobiotic metabolism of hydrophobic compounds. Particularly, the mammalian CYP1–3 families are involved in metabolizing xenobiotics such as pesticides and environmental pollutants (Inui et al., 2001). The substrate-binding cavity is situated in the P450 enzyme, and the heme iron, located at the cavity's bottom, activates an oxygen molecule using electrons from NADPH. The substrate-binding cavities of P450 enzymes can accommodate various chemicals with different structures and use them as substrates. Therefore, one P450 species can oxidize multiple types of xenobiotics.

Polychlorinated biphenyls (PCBs) are chemically stable and thus are widely used in commercial products such as transformers and condensers. However, because of their extremely hydrophobic and persistent chemical properties, PCBs released into the environment accumulate in apex predators through food chains. Accumulation of high levels of PCBs in animals causes adverse effects, including carcinogenicity and teratogenicity. Therefore, PCBs have been registered as persistent organic pollutants (<http://www.pops.int>). Although there are theoretically 209 PCB congeners, 12 PCBs with a planar structure have dioxin-like toxicity. These 12 congeners are known as dioxin-like PCBs and have toxic equivalency factor (TEF) values reflecting the extent of their toxicity (Van den Berg et al., 2006). Therefore, the metabolic fate of dioxin-like PCBs should be clarified to determine their toxicity.

An important step in PCB metabolism is oxidation by P450 species in the Phase I reaction. Dioxin-like PCBs are metabolized to hydroxylated (OH) metabolites by the CYP1A and CYP2B

subfamilies (Yamazaki et al., 2011; Mise et al., 2016). The non-*ortho*-substituted PCB, 3,3',4,4',5-pentachlorobiphenyl (CB126), which exhibits the highest dioxin-like toxicity among PCB congeners, is metabolized by rat CYP1A1 to OH-metabolites (Yamazaki et al., 2011). In contrast, human CYP2B6 metabolizes mono-*ortho* substituted PCB, 2,3',4,4',5-pentachlorobiphenyl (CB118) to OH-metabolites (Mise et al., 2016). Hydroxylation of PCBs contributes to detoxification by increasing their sensitivity to further detoxifying systems, such as conjugation in Phase II reactions (Yoshimura et al., 1987; Haraguchi et al., 1997). Dechlorinated OH-tetrachloro-metabolites of CB126 and CB118 are produced concomitantly with OH-pentachloro-metabolites, and dechlorination greatly decreases dioxin-like toxicity by increasing water solubility. Compared to human CYP1A1, rat CYP1A1 exhibited higher metabolizing activity toward CB126, suggesting that humans are more sensitive than rats to CB126 toxicity. In contrast, CB118 was metabolized to a greater extent by human CYP2B6 than by rat CYP1A1 and CYP2B1. These results indicate the difficulty in extrapolating metabolic data using experimental animals for human risk evaluation. Therefore, *in vitro* studies are needed to compare the metabolizing activities of rat and human P450 enzymes.

3,3',4,4'-Tetrachlorobiphenyl (CB77) is relatively abundant in the environment and eventually accumulates in organisms (Nunes et al., 2011). The CB77 metabolites, 4'-OH-3,3',4,5'-tetrachlorobiphenyl (CB79) and 5-OH-CB77, were detected in the feces of CB77-administered rats (Yoshimura et al., 1987). P450 species inducibly produced in hepatic microsomes prepared from rats administered with the typical CYP1A inducer 3-methylcholanthrene (MC) increased the levels of these CB77 metabolites (Ishida et al., 1991). This result suggests that CYP1A is responsible for CB77 metabolism in rats. Furthermore, metabolism studies using scup (White et al., 1997), channel catfish (Doi et al., 2006), chick embryos (Klasson Wehler et al., 1990), and

beluga and pilot whales (White et al., 1997) revealed other CB77 metabolites such as 2-OH-CB77 and 6-OH-CB79. These studies indicate that PCB metabolites differ depending on the species. However, information regarding CB77 metabolism by human CYP1A1 is limited.

In this study, the metabolic activities of recombinant rat and human CYP1A1s toward CB77 were measured, and their differences in CB77 metabolism were clarified by comparing their 3D structures and docking models with CB77. Rat and human CYP1A1s have a high amino acid identity (79%) and similar 3D structures (Yamazaki et al., 2011). Thus, amino acids responsible for the differences in the metabolic activities of CB77 between rat and human CYP1A1s can be identified.

## **2. Materials and methods**

### *2.1. Chemicals and reagents*

Microsomes from insect cells expressing rat or human *CYP1A1* and rat or human NADPH-cytochrome P450 oxidoreductase genes were purchased from BD Biosciences (San Jose, CA, USA). CB77 (AccuStandard, New Haven, CT, USA) was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 2,000 µg/mL. A <sup>13</sup>C-Labeled OH-PCB mixture, used as the internal standard, and [<sup>13</sup>C<sub>12</sub>]-2,3',4',5-tetrachlorobiphenyl, used as the syringe spike, were purchased from Wellington Laboratories (Ontario, Canada).

### *2.2. Measurement of catalytic activities of rat and human CYP1A1s and their mutants toward CB77*

The reaction mixtures contained CB77 at a final DMSO concentration of 0.1% (v/v), microsomes containing 80 nM of either rat or human CYP1A1, 3.3 mM magnesium chloride, and an NADPH regeneration system (5 mM glucose-6-phosphate and 1 U of glucose-6-phosphate dehydrogenase) in 100 mM potassium phosphate buffer at pH 7.4. This mixture was allowed to react for 2 h at 37 °C following the addition of NADPH at a final concentration of 0.5 mM. After adding 10 µL of 100 ng/mL <sup>13</sup>C-labeled OH-PCB mixture as an internal standard, the metabolites were extracted with four volumes of hexane and methylated as described previously (Sakiyama et al., 2007). OH-PCBs were identified and quantified using a high-resolution gas chromatography-mass spectrometer (HRGC/HRMS) under previously described conditions (Goto et al., 2018). The catalytic activities of rat and human CYP1A1s and their mutants produced in the microsomal fractions of recombinant *Saccharomyces cerevisiae* toward CB77 were also measured.

### 2.3. Construction of rat and human CYP1A1 mutants

Rat and human CYP1A1 genes in pUC18 were transferred into the *Escherichia coli* strain JM109. Site-directed mutagenesis was performed using the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) with primers containing T946C and G358T mutations for rat CYP1A1 and G936T, A346G, and G347C mutations for human CYP1A1 (Table S1). These mutations were confirmed using DNA sequencing. Rat and human CYP1A1 mutant coding sequences were inserted at the HindIII sites of the pGYR expression plasmid containing yeast NADPH-cytochrome P450 oxidoreductase (YR) genes, resulting in the pGYR/r1A1mutant and pGYR/h1A1mutant, respectively. Plasmids containing cDNAs of wild-type rats and human CYP1A1s were also constructed and introduced into the *S. cerevisiae* AH22 strain using a one-step yeast transformation method (Chen et al., 1992).

#### 2.4. Preparation of microsomal fractions from recombinant *S. cerevisiae*

Recombinant *S. cerevisiae* AH22/pGYRr1A1, AH22/pGYRr1A1mutant, AH22/pGYRh1A1, and AH22/pGYRh1A1mutant cells expressing rat *CYP1A1*, rat *CYP1A1* mutant, human *CYP1A1*, and human *CYP1A1* mutant, respectively, as well as *YR* genes were pre-cultured in synthetic minimum medium containing 8% (w/v) glucose, 0.67% (w/v) yeast nitrogen base without amino acids, and 160 mg/L L-histidine for 20 h at 30 °C. The culture was then transferred to medium containing 8% (w/v) glucose, 1% (w/v) yeast extract, 2% (w/v) peptone, and 40 mg/L adenine sulfate and incubated for 20 h at 30 °C. Microsomal fractions were prepared as previously described (Oeda et al., 1985). Protein concentrations were measured using the Bradford method (Bradford, 1976) with bovine serum albumin as the standard. The amounts of P450s in the microsomal fractions were determined from the reduced CO difference spectra (Omura and Sato, 1964). The levels of rat and human CYP1A1s and rat and human CYP1A1 mutants in the microsomes were 110, 24.2, 15.8, and 7.61 pmol/mg microsomal protein, respectively (Table S2).

#### 2.5. Measurement of 7-ethoxycoumalin O-deethylation activity of *CYP1A1*s

The 7-ethoxycoumalin O-deethylation (ECOD) activities of rat and human CYP1A1s and their mutants in the yeast microsomal fractions were measured. The reaction mixture (0.5 mL) contained 0.26 mM 7-ethoxycoumarin dissolved in 60% (v/v) methanol; microsomes containing 80 nM of either rat, human CYP1A1, or their mutants; and an NADPH regeneration system in 100 mM potassium phosphate buffer at pH 7.4. The reaction was initiated by adding NADPH at a final concentration of 0.5 mM. After incubation for 1 h at 37 °C and the addition of 30% (v/v) trichloroacetic acid, the reactants were vortexed and centrifuged at 2,000 rpm for 5 min at 4 °C. The supernatant (400 µL) was separated and mixed with a 2-fold volume of chloroform. The



organic phase (500  $\mu$ L) was collected and mixed with 1 mL of 0.01 M sodium hydroxide and 0.1 M sodium chloride. After centrifugation at 12,000 rpm for 5 min at 4 °C, the supernatant was collected, and fluorescence was measured at excitation and emission wavelengths of 366 and 452 nm, respectively.

## *2.6. Homology modeling and substrate docking*

In previous studies, a 3D model of human CYP1A1 was constructed based on the X-ray crystal structure of human CYP1A2 (Sansen et al., 2007; Itoh et al., 2010), and then a 3D model of rat CYP1A1 based on the human CYP1A1 model was constructed (Yamazaki et al., 2011). Models of the rat and human CYP1A1 mutants based on the rat and human CYP1A1 models, respectively, were constructed using the “Mutate monomers” tool in SYBYL Biopolymer (Tripos, St Louis, MO, USA).


Docking was performed using Surflex Dock in SYBYL 8.0 (Tripos), as previously described (Yamazaki et al., 2011). Human and rat CYP1A1 models and their mutants were used as the CYP protein structure. Diverse substrate structure orientations for rat and human CYP1A1s, their mutants, and selected substrate structures with the top 25 ranked candidates based on the weighted sum of the scoring functions were obtained.

## **3. Results and discussion**

### *3.1. Catalytic activity of rat and human CYP1A1s toward CB77*

Chromatographic peaks corresponding to methylated mono-OH tetrachlorobiphenyl M1 and methylated mono-OH trichlorobiphenyl M2 increased in intensity when microsomes containing


rat CYP1A1s in the presence of NADPH were analyzed (Fig. 1C–F). In contrast, only M1 was detected in an NADPH-dependent manner when microsomes containing human CYP1A1 were used (Fig. 1G–J). Control microsomes that did not contain any CYP1A1 showed no peaks (Fig. S1). The pattern of retention times of M1 and M2 were identical to those of the authentic standard S1, which is 5-MeO-2,3',4,4'-tetrachlorobiphenyl (CB66) or 4'-MeO-CB79, and S2, which is 4'-MeO-3,3',4-trichlorobiphenyl (CB35) (Fig. 1A–D, G, H). These M1 and M2 peaks also matched the isotope ratios ( $[M]^+:[M+2]^+$ ) of the authentic standards S1 and S2, indicating that the peaks were from tetra- and trichlorinated compounds, respectively (Fig. S2). In addition, the patterns of fragment ions in the mass spectrum were examined to determine the position of the OH-group on the biphenyl ring (Fig. S3). The upper  $[M-CH_3Cl]^+$  and lower  $[M-COCH_3]^+$  peaks indicated that the substituted OH-group was at the *ortho*- and *meta*- or *para*-positions, respectively (Kunisue and Tanabe, 2009). The M1 peak was observed in both  $[M-CH_3Cl]^+$  and  $[M-COCH_3]^+$  with the same intensity, indicating that M1 could have an OH-group in all positions, and the M2 peak was observed in  $[M-COCH_3]^+$ , indicating that M2 had an OH-group in the *meta*- or *para*-position. A comparison of the retention times of the authentic standards and isotope ratios indicated that M1 was 5-OH-CB66 or 4'-OH-CB79. Considering previous studies of CB77 metabolism (Ishida et al., 1991; Murk et al., 1994; Morse et al., 1995), we predicted that M1 is 4'-OH-CB79, produced by hydroxylation of the 4-position in the biphenyl ring through the epoxide intermediate followed by migration of a chlorine atom caused by an NIH shift from the 4- to the 5-position (Gordon et al., 1967). This prediction is reasonable because it is unlikely that 5-OH-CB66 is produced by hydroxylation at the 5-position followed by migration of a chlorine atom from the 3- to 2-position. In contrast, M2 was identified as 4'-OH-CB35 by hydroxylation and dechlorination of the 4-position through electrophilic substitution (Hackett et al., 2007).



**Fig. 1.** Detection of tetrachlorobiphenyl (C, E, G, I) and trichlorobiphenyl (D, F, H, J) metabolites from 3,3',4,4'-tetrachlorobiphenyl (CB77) reacted with rat (C–F) and human (G–J) CYP1A1s by high-resolution gas chromatography/high-resolution mass spectrometry. A and B, peak S1, 5-MeO-2,3',4,4'- or 4'-MeO-3,3',4,5'-tetrachlorobiphenyl; peak S2, 4'-MeO-3,3',4-trichlorobiphenyl. C and D, rat CYP1A1 with NADPH. E and F, rat CYP1A1 without NADPH. G and H, human

CYP1A1 with NADPH. I and J, human CYP1A1 without NADPH. The insets in G and I show the magnified graphs.

Both peaks corresponding to M1 and M2 in the microsomes containing rat CYP1A1 were much larger than those containing human CYP1A1. The kinetic parameters of rat and human CYP1A1s for the production of 4'-OH-CB79 and 4'-OH-CB35 were determined using the Michaelis–Menten equation (Fig. S4A–C) and Lineweaver–Burk plot (Fig. S4D–F). The  $V_{\max}/K_m$  of rat CYP1A1 toward the production of 4'-OH-CB79 was >150-fold higher than that of human CYP1A1 (Table 1). Similarly, the  $V_{\max}/K_m$  of rat CYP1A1 toward the production of 4'-OH-CB35 was 2.68, whereas 4'-OH-CB35 was not detected in human CYP1A1. These results indicate that rat CYP1A1 has much higher activity toward CB77 metabolism than human CYP1A1. Fig. 2 shows the proposed metabolic pathways for CB77 based on rat and human CYP1A1s. The OH-metabolites generated by the NIH shift and dechlorination were also detected in previous studies (Liu et al., 2020). The feces from intraperitoneally CB77-injected rats contained 5-OH-CB77 and 4'-OH-CB79 as major metabolites and 4'-OH-CB35 as a minor metabolite (Yoshimura et al., 1987; Koga et al., 1989). The livers of rats orally administered with CB77 contained a higher level of 4'-OH-CB79 compared to the level of 5-OH-CB77 (Morse et al., 1995). In *in vitro* experiments using liver microsomes from rats treated with MC, 4'-OH-CB79 was detected as a major metabolite (Ishida et al., 1991). Another *in vitro* experiment using the CYP1A inducer  $\beta$ -naphthoflavone revealed the production of 4'-OH-CB79, 5-OH-CB77, and 6-OH-CB77 (Morse et al., 1995). These results strongly suggest that CYP1A1 is responsible for CB77 metabolism and that 4'-OH-CB79 is a primary metabolite.




**Fig. 2.** Proposed metabolic pathways of 3,3',4,4'-tetrachlorobiphenyl (CB77) by rat and human CYP1A1s. M1 was predicted as 4'-OH-3,3',4,5'-tetrachlorobiphenyl and M2 was identified as 4'-OH-3,3',4-trichlorobiphenyl.

### 3.2. Docking studies of rat and human CYP1A1s with CB77

The substrate-binding cavities of rat and human CYP1A1s were well-conserved except for four residues in rat (A120, T126, S225, and F316) and human (S116, S122, N221, and L312) CYP1A1s (Yamazaki et al., 2011). Two of the four residues (A120 and F316 in rat CYP1A1; S116 and L312 in human CYP1A1) caused a large spatial structural change, resulting in a difference in the cavity volumes ( $510 \text{ \AA}^3$  in rat CYP1A1 and  $600 \text{ \AA}^3$  in human CYP1A1). For CB126 metabolism, the smaller volume of the rat CYP1A1 cavity resulted in a more stable accommodation of CB126 when compared with the human CYP1A1, resulting in the high metabolizing activity of rat CYP1A1 (Yamazaki et al., 2011).

239 Docking studies of rat and human CYP1A1s with CB77 were performed to understand their  
240 interaction. CB77 showed distinct orientations in each CYP1A1; the structures were classified into  
241 three and six orientations toward rat and human CYP1A1s, respectively (Fig. 3A, B). As rat  
242 CYP1A1 accommodates CB77 with fewer orientations than human CYP1A1, CB77 is stable in  
243 the substrate-binding cavity of rat CYP1A1, leading to high activity. Furthermore, all orientations  
244 in rat CYP1A1 were directed to the iron atom of heme, which is the active center of P450s. In  
245 contrast, human CYP1A1 accommodates CB77 in multiple orientations, and most of the  
246 orientations of CB77 in human CYP1A1 are distant from the heme iron. CB77 was less than 5 Å  
247 from the heme iron in eight and three conformations in rat and human CYP1A1, respectively (Fig.  
248 3C, D). Proximity is an important factor related to the high activity (Yamazaki et al., 2011), and a  
249 distance of 5 Å is sufficient for CB77 to react with CYP1A1s. These results indicate that rat  
250 CYP1A1 shows higher activity than human CYP1A1 because of the stable accommodation and  
251 proximity of CB77. Docking studies also provided insight into the hydroxylation position of CB77.  
252 The 4-position of CB77 accessed the heme, supporting that 4'-OH-CB79 and 4'-OH-CB35 were  
253 produced.




**Fig. 3.** Docking models of rat (A, C) and human (B, D) CYP1A1s with 3,3',4,4'-tetrachlorobiphenyl (CB77). The Connolly channel surfaces of the cavities are displayed using a colored mesh. A and B depict representative orientations of CB77 in the substrate-binding cavity of rat (three orientations) and human (six orientations) CYP1A1s; C and D depict the conformations of CB77 close to the heme iron (less than 5 Å) in rats (eight conformations) and human (three conformations) CYP1A1s.

The dechlorinated OH-metabolite M2 was detected at much lower levels than the OH-metabolite M1 (Fig. 1C, D). CB77 has a TEF value of 0.0001, indicating that dioxin-like toxicity is caused by CB77 accumulation in mammals (Van den Berg et al., 2006). However, no trichlorinated biphenyls showed a TEF value, suggesting that dechlorination of

tetrachlorobiphenyls eliminates dioxin-like toxicity. Thus, the mechanisms underlying the dechlorination of CB77 were evaluated using docking models.

CB77 shows two conformations (conformations A and B, Fig. 4) in the substrate-binding cavity of rat CYP1A1 close to the heme. The 4- and 5- and the 3- and 4-positions of CB77 are directed to the oxygen atom of heme in conformations A and B, respectively. Because both the 4- and 5-positions of CB77 are equally close to the oxygen atom in conformation A, 4,5-epoxide is formed, resulting in an NIH shift of the chlorine group from the 4- to the 5-position. This reaction results in the formation of 4'-OH-CB79 (metabolite M1) and not 5'-OH-CB77. In contrast, the 3- and 4-positions of CB77 are sufficiently close ( $<4 \text{ \AA}$ ) to the oxygen atom to form epoxide (Fig. 4) (Hata et al., 2008). However, if epoxidation occurs, the final product cannot be a phenolic compound. Therefore, electrophilic substitution should be performed to form dechlorinated OH-metabolite M2. An electrophilic attack occurs at the 4-position of CB77 by the oxygen atom, resulting in the elimination of the chlorine atom (Hackett et al., 2007). However, it is difficult to show the advantages of conformation A, although more M1 than M2 is produced. To this end, there are two possibilities: first, steric hindrance between the chlorine group at the 3-position in conformation B and Thr126, which comprise the substrate-binding cavity; and second, the efficiency of epoxidation, which is much higher than that of electrophilic substitution.





**Fig. 4.** Proposed conformations of 3,3',4,4'-tetrachlorobiphenyl (CB77) in the substrate-binding cavity of rat CYP1A1 to produce hydroxylated tetrachlorobiphenyl and hydroxylated trichlorobiphenyl metabolites. Conformations A and B of CB77 produced M1, predicted as 4'-OH-3,3',4,5'-tetrachlorobiphenyl, and M2, identified as 4'-OH-3,3',4-trichlorobiphenyl.

### 3.3. Measurement of metabolic activities of CYP1A1 mutants

Two amino acids constituting the substrate-binding cavity of rat and human CYP1A1s play important roles in CB126 metabolism (Yamazaki et al., 2011). Therefore, the reciprocal mutations A120S and F319L were introduced in rat CYP1A1, and S116A and L312F were introduced in

human CYP1A1 to clarify the importance of these amino acids in CB77 metabolism. The mutated sites of *CYP1A1* genes were confirmed using DNA sequencing (Fig. S5). After introducing plasmids containing each *P450* into *S. cerevisiae*, the P450 content was determined from the reduced CO difference spectra in the microsomes. All microsomes showed absorption maxima at approximately 450 nm, but their contents varied among the P450s (Fig. S6 and Table S2). The P450 content of each mutant was lower than that of the wild-type, and the production of rat CYP1A1 was higher than that of human CYP1A1. Human CYP1A1 and its mutant were not stably produced in *S. cerevisiae* compared with rat CYP1A1 and its mutant.

The ECOD activity of the microsomes containing rat CYP1A1 mutant decreased significantly by 10% compared with that of wild-type rat CYP1A1 (Table S2). In contrast, mutant human CYP1A1 showed significantly higher activity (2.4-fold) than wild-type human CYP1A1. Therefore, the two amino acids may be responsible for metabolic activity by changing the shape and volume of the substrate-binding cavity.

Rat CYP1A1 mutant showed a decrease in hydroxylation activity to produce M1 at all tested concentrations of CB77 (Fig. S7A). The  $V_{\max}/K_m$  in the mutant enzyme decreased by approximately 30% compared to that in the wild-type enzyme (Table 2). In contrast, the mutant enzyme showed higher production of M2, which is a dechlorinated OH-metabolite, compared to that of the wild-type enzyme (Fig. S7B). The activity of the mutant enzyme was 3.9-fold higher than that of the wild-type enzyme (Table 2). This result was unexpected because mutation of amino acids in rat CYP1A1 to a human CYP1A1 led to decreased ECOD activity and production of M1. In contrast, human CYP1A1 and its mutant showed no hydroxylation activity, possibly because two other amino acids, T126 and S225, which comprise the substrate-binding cavity of rat CYP1A1, are also important for CB77 metabolism.

### 3.4. Docking studies of rat and human CYP1A1 mutants with CB77

CB77 in the substrate-binding cavity of rat and human CYP1A1 mutants showed five and four orientations, respectively (Fig. S8A, B). With these mutations, the cavity of rat CYP1A1 mutant was enlarged, and orientations not directed to the heme emerged (Fig. S8A). Concomitantly, the conformations of CB77 in the cavity were scattered (Fig. S8C), resulting in unstable accommodation of CB77 in the cavity and low metabolizing activities. In contrast, the cavity shape of the human CYP1A1 mutant was similar to that of the rat CYP1A1 wild-type after the introduction of F312, and most orientations were directed to the heme (Fig. 3A and Fig. S8B). As a result, the number of conformations close to the heme increased (Fig. S8D). As human CYP1A1 mutant with mutations at S116A and L312F did not metabolize CB77, the mutant containing S122T and N221S will be used in further studies.

The detailed mechanisms of the contrasting activities toward M1 and M2 production were examined in docking studies. In wild-type rat CYP1A1, the phenyl ring of F316 squeezes the 4- and 5-positions of CB77 close to the heme at distances of 4.9 and 4.8 Å, respectively, resulting in the production of M1 (Fig. S9A, CB77 shown in red). In contrast, the rat CYP1A1 mutant F316L without a phenyl ring cannot squeeze CB77, leading to a distance of 5.4 Å between the 5-position and heme (Fig. S9A, CB77 shown in blue), thereby conferring low hydroxylation activity towards CB77 with an NIH shift. Dechlorinated OH-metabolite M2 showed higher production in the mutant than in the wild-type; the bulky side-chain of F316 limits the conformation of CB77 because of the vicinity (2.4 Å) of the chlorine group at the 3'-position of CB77 (Fig. S9B). In contrast, after introducing F316L, conformations without conflicts and whose 3- and 4-positions were close to the heme tended to increase, as described in two conformations of CB77 in blue

compared with one conformation in red. These effects led to an increase in the dechlorination activity of the mutant.

#### 4. Conclusions

We predicted the structural basis of CB77 metabolism by rat and human CYP1A1s. We concluded that stable accommodation of CB77 in the substrate-binding cavity and the proximity of CB77 to heme are important for achieving efficient hydroxylation and dechlorination. Rat CYP1A1 showed much higher hydroxylation and dechlorination activities compared with human CYP1A1. These results are consistent with the metabolism of CB126 (Yamazaki et al., 2011) and suggest that humans have low metabolizing activities toward dioxin-like PCBs compared with rat CYP1A1. These PCBs have high TEF values among PCB congeners, indicating that they cause dioxin-like toxicity in human bodies. This suggests that humans are more sensitive to dioxin-like PCBs than experimental animals, such as rats. The underlying mechanisms were determined by identifying the amino acids responsible for CB77 metabolism. Detailed dechlorination mechanisms were proposed by constructing docking models; however, enhanced metabolic activity toward CB77 by the human CYP1A1 mutant was not observed. Further studies are needed to evaluate whether other amino acid mutations in the substrate-binding cavity of human CYP1A1 can affect CB77 metabolism. Determining the dechlorination mechanisms will lead to the development of metabolizing enzymes that can drastically decrease dioxin-like toxicity (Yoshimura et al., 1987). A promising approach to utilizing such enzymes is phytoremediation. Several P450 species have been introduced into transgenic plants to degrade PCBs (Aken et al.,

2010; Shimazu et al., 2011). Dechlorination-enhanced mutants are a prospective tool for cleaning dioxin-like PCBs in contaminated environments.

## **Author Contributions**

**Miku Yabu:** Data curation, Formal analysis, Investigation, Roles/Writing - original draft. **Yuki Haga :** Data curation, Formal analysis, Investigation. **Toshimasa Itoh :** Data curation, Formal analysis, Investigation. **Erika Goto:** Data curation, Investigation. **Motoharu Suzuki :** Data curation, Formal analysis, Investigation. **Kiyoshi Yamazaki :** Data curation, Formal analysis, Investigation. **Shintaro Mise :** Data curation, Investigation. **Keiko Yamamoto:** Data curation, Formal analysis, Validation. **Chisato Matsumura :** Data curation, Validation. **Takeshi Nakano:** Methodology, Validation. **Toshiyuki Sakaki:** Methodology, Validation. **Hideyuki Inui:** Conceptualization, Data curation, Funding acquisition, Project administration, Roles/Writing - original draft.

## **Funding Sources**

This work was supported by the Ministry of Agriculture, Forestry and Fisheries of Japan [grant number HC-06-2311-1 to HI] and Genomics for Agricultural Innovation [grant number GMB-0006 to HI].

## **Acknowledgments**

We thank Yuko Ishida and Harunobu Tsuzuki for sample preparation. We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

**Table 1** Kinetic parameters of rat and human CYP1A1s for hydroxylation and dechlorination of 3,3',4,4'-tetrachlorobiphenyl (CB77).

CYP1A1	4'-OH-3,3',4,5'-Tetrachlorobiphenyl			4'-OH-3,3',4-Trichlorobiphenyl		
	$K_m^1$	$V_{max}^2$	$V_{max}/K_m$	$K_m$	$V_{max}$	$V_{max}/K_m$
Rat	10.3	1590	153	3.60	9.66	2.68
Human	7.74	7.54	0.975	ND <sup>3</sup>	ND	-

<sup>1</sup>  $\mu$ M; <sup>2</sup> pmol/min/(nmol P450); <sup>3</sup> not detected.

**Table 2** Kinetic parameters of rat CYP1A1 and its mutant for hydroxylation and dechlorination of 3,3',4,4'-tetrachlorobiphenyl (CB77).

Rat CYP1A1	4'-OH-3,3',4,5'-Tetrachlorobiphenyl			4'-OH-3,3',4-Trichlorobiphenyl		
	$K_m^1$	$V_{max}^2$	$V_{max}/K_m$	$K_m$	$V_{max}$	$V_{max}/K_m$
WT	7.47	830	111	53.4	238	4.46
Mutant	4.99	375	75.2	2.18	38.5	17.6

<sup>1</sup>  $\mu$ M; <sup>2</sup> pmol/min/(nmol P450)

## References

- Van Aken, B., Correa, P.A., Schnoor, J.L., 2010. Phytoremediation of polychlorinated biphenyls: new trends and promises. *Environ. Sci. Technol.* 44, 2767–2776. <https://doi.org/10.1021/es902514d>.
- Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72, 248–254. [https://doi.org/10.1016/0003-2697\(76\)90527-3](https://doi.org/10.1016/0003-2697(76)90527-3).
- Chen, D.C., Yang, B.C., Kuo, T.T., 1992. One-step transformation of yeast in stationary phase. *Curr. Genet.* 21, 83–84. <https://doi.org/10.1007/BF00318659>.
- Doi, A.M., Lou, Z., Holmes, E., Venugopal, C.S., Nyagode, B., James, M.O., Kleinow, K.M., 2006. Intestinal bioavailability and biotransformation of 3,3',4,4'- tetrachlorobiphenyl (CB 77) in in situ preparations of channel catfish following dietary induction of CYP1A. *Aquat. Toxicol.* 77, 33–42. <https://doi.org/10.1016/j.aquatox.2005.10.013>.
- Gordon, G., Daly, J.W., Jerina, D.M., Renson, J., Witkop, B., Udenfriend, S., 1967. Hydroxylation-induced migration: The NIH shift. *Science* 157, 1524–1530. <https://doi.org/10.1126/science.157.3796.1524>.
- Goto, E., Haga, Y., Kubo, M., Itoh, T., Kasai, C., Shoji, O., Yamamoto, K., Matsumura, C., Nakano, T., Inui, H., 2018. Metabolic enhancement of 2,3',4,4',5-pentachlorobiphenyl (CB118) using cytochrome P450 monooxygenase isolated from soil bacterium under the presence of perfluorocarboxylic acids (PFCAs) and the structural basis of its metabolism. *Chemosphere* 210, 376–383. <https://doi.org/10.1016/j.chemosphere.2018.07.026>.

412 Hackett, J.C., Sanan, T.T., Hadad, C.M., 2007. Oxidative dehalogenation of perhalogenated  
 413 benzenes by cytochrome P450 compound I. *Biochemistry* 46, 5924–5940.  
 414 <https://doi.org/10.1021/bi700365x>.

415 Haraguchi, K., Kato, Y., Masuda, Y., Kimura, R., 1997. Metabolism of 3,3',4,4'-  
 416 tetrachlorobiphenyl via sulphur-containing pathway in rat: liver-specific retention of  
 417 methylsulphonyl metabolite. *Xenobiotica* 27, 831–842.  
 418 <https://doi.org/10.1080/004982597240190>.

419 Hata, M., Tanaka, Y., Kyoda, N., Osakabe, T., Yuki, H., Ishii, I., Kitada, M., Neya, S., Hoshino,  
 420 T., 2008. An epoxidation mechanism of carbamazepine by CYP3A4. *Bioorganic Med. Chem.*  
 421 16, 5134–5148. <https://doi.org/10.1016/j.bmc.2008.03.023>.

422 Inui, H., Shiota, N., Motoi, Y., Ido, Y., Inoue, T., Kodama, T., Ohkawa, Y., Ohkawa, H., 2001.  
 423 Metabolism of herbicides and other chemicals in human cytochrome P450 species and in  
 424 transgenic potato plants co-expressing human CYP1A1, CYP2B6 and CYP2C19. *J. Pestic.*  
 425 *Sci.* 26, 28–40. <https://doi.org/10.1584/jpestics.26.28>.

426 Ishida, C., Koga, N., Hanioka, N., Saeki, H.K., Yoshimura, H., 1991. Metabolism *in vitro* of  
 427 3,4,3',4'- and 2,5,2',5'-tetrachlorobiphenyl by rat liver microsomes and highly purified  
 428 cytochrome P-450. *J. Pharmacobiodyn.* 14, 276–284.  
 429 <https://doi.org/10.1248/bpb1978.14.276>.

430 Itoh, T., Takemura, H., Shimoi, K., Yamamoto, K., 2010. A 3D model of CYP1B1 explains the  
 431 dominant 4-hydroxylation of estradiol. *J. Chem. Inf. Model.* 50, 1173–1178.  
 432 <https://doi.org/10.1021/ci1000554>.



433 Klasson Wehler, E., Brunström, B., Rannug, U., Bergman, Å., 1990. 3,3',4,4'-  
 434 Tetrachlorobiphenyl: Metabolism by the chick embryo in ovo and toxicity of hydroxylated  
 435 metabolites. *Chem. Biol. Interact.* 73, 121–132. [https://doi.org/10.1016/0009-](https://doi.org/10.1016/0009-2797(90)90112-Z)  
 436 2797(90)90112-Z.

437 Koga, N., Beppu, M., Ishida, C., Yoshimura, H., 1989. Further studies on metabolism in vivo of  
 438 3,4,3',4'-tetrachlorobiphenyl in rats: Identification of minor metabolites in rat faeces.  
 439 *Xenobiotica* 19, 1307–1318. <https://doi.org/10.3109/00498258909043182>.

440 Kunisue, T., Tanabe, S., 2009. Hydroxylated polychlorinated biphenyls (OH-PCBs) in the blood  
 441 of mammals and birds from Japan: Lower chlorinated OH-PCBs and profiles. *Chemosphere*  
 442 74, 950–961. <https://doi.org/10.1016/j.chemosphere.2008.10.038>.

443 Liu, J., Tan, Y., Song, E., Song, Y., 2020. A critical review of polychlorinated biphenyls  
 444 metabolism, metabolites, and their correlation with oxidative stress. *Chem. Res. Toxicol.* 33,  
 445 2022–2042. <https://doi.org/10.1021/acs.chemrestox.0c00078>.

446 Mise, S., Haga, Y., Itoh, T., Kato, A., Fukuda, I., Goto, E., Yamamoto, K., Yabu, M., Matsumura,  
 447 C., Nakano, T., Sakaki, T., Inui, H., 2016. Structural determinants of the position of  
 448 2,3',4,4',5-pentachlorobiphenyl (CB118) hydroxylation by mammalian cytochrome P450  
 449 monooxygenases. *Toxicol. Sci.* 152, 340–348. <https://doi.org/10.1093/toxsci/kfw086>.

450 Morse, D.C., Van Bladeren, P.J., Klasson Wehler, E., Brouwer, A., 1995.  $\beta$ -Naphthoflavone- and  
 451 self-induced metabolism of 3,3',4,4'-tetrachlorobiphenyl in hepatic microsomes of the male,  
 452 pregnant female and foetal rat. *Xenobiotica* 25, 245–260.  
 453 <https://doi.org/10.3109/00498259509061849>.

454 Morse, D.C., Klasson Wehler, E., van de Pass, M., de Bie, A.T.H.J., Bladeren, P.J. Van, Brouwer,  
 455 A., 1995. Metabolism and biochemical effects of 3,3',4,4'-tetrachlorobiphenyl in pregnant  
 456 and fetal rats 95, 41–56. [https://doi.org/10.1016/0009-2797\(94\)03347-1](https://doi.org/10.1016/0009-2797(94)03347-1)

457 Murk, A., Morse, D., Boon, J., Brouwer, A., 1994. In vitro metabolism of 3,3',4,4'-  
 458 tetrachlorobiphenyl in relation to ethoxyresorufin-*O*-deethylase activity in liver microsomes  
 459 of some wildlife species and rat. Eur. J. Pharmacol. Environ. Toxicol. 270, 253–261.  
 460 [https://doi.org/10.1016/0926-6917\(94\)90069-8](https://doi.org/10.1016/0926-6917(94)90069-8).

461 Nunes, M., Marchand, P., Vernisseau, A., Bizec, B. Le, Ramos, F., Pardal, M.A., 2011. PCDD/Fs  
 462 and dioxin-like PCBs in sediment and biota from the Mondego estuary (Portugal).  
 463 Chemosphere 83, 1345–1352. <https://doi.org/10.1016/j.chemosphere.2011.02.081>.

464 Oeda, K., Sakaki, T., Ohkawa, H., 1985. Expression of rat liver cytochrome P-450MC cDNA in  
 465 *Saccharomyces cerevisiae*. DNA 4, 203–210. <https://doi.org/10.1089/dna.1985.4.203>.

466 Omura, T., Sato, R., 1964. The carbon monoxide-binding pigment of liver microsomes: I.  
 467 Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370–2378.  
 468 [https://doi.org/10.1016/S0021-9258\(20\)82244-3](https://doi.org/10.1016/S0021-9258(20)82244-3).

469 Sakiyama, T., Yamamoto, A., Kakutani, N., Fukuyama, J., Okumura, T., 2007. Hydroxylated  
 470 polychlorinated biphenyls (OH-PCBs) in the aquatic environment: Levels and congener  
 471 profiles in sediments from Osaka. Japan. Organohal. Comp. 69, 1380–1383.

472 Sansen, S., Yano, J.K., Reynald, R.L., Schoch, G.A., Griffin, K.J., Stout, C.D., Johnson, E.F., 2007.  
 473 Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure

474 of human P450 1A2. J. Biol. Chem. 282, 14348–14355.  
 475 <https://doi.org/10.1074/jbc.M611692200>.

476 Shimazu, S., Inui, H., Ohkawa, H., 2011. Phytomonitoring and phytoremediation of agrochemicals  
 477 and related compounds based on recombinant cytochrome P450s and aryl hydrocarbon  
 478 receptors (AhRs). J. Agric. Food Chem. 59, 2870–2875. <https://doi.org/10.1021/jf102561d>.

479 Van den Berg, M., Birnbaum, L.S., Denison, M., De Vito, M., Farland, W., Feeley, M., Fiedler,  
 480 H., Hakansson, H., Hanberg, A., Haws, L., Rose, M., Safe, S., Schrenk, D., Tohyama, C.,  
 481 Tritscher, A., Tuomisto, J., Tysklind, M., Walker, N., Peterson, R.E., 2006. The 2005 World  
 482 Health Organization reevaluation of human and mammalian toxic equivalency factors for  
 483 dioxins and dioxin-like compounds. Toxicol. Sci. 93, 223–241.  
 484 <https://doi.org/10.1093/toxsci/kfl055>.

485 White, R.D., Shea, D., Stegeman, J.J., 1997. Metabolism of the aryl hydrocarbon receptor agonist  
 486 3,3',4,4'-tetrachlorobiphenyl by the marine fish scup (*Stenotomus chrysops*) *in vivo* and *in*  
 487 *vitro*. Drug Metab. Dispos. 25, 564–572.

488 Yamazaki, K., Suzuki, M., Itoh, T., Yamamoto, K., Kanemitsu, M., Matsumura, C., Nakano, T.,  
 489 Sakaki, T., Fukami, Y., Imaishi, H., Inui, H., 2011. Structural basis of species differences  
 490 between human and experimental animal CYP1A1s in metabolism of 3,3',4,4',5-  
 491 pentachlorobiphenyl. J. Biochem. 149, 487–494. <https://doi.org/10.1093/jb/mvr009>.

492 Yoshimura, H., Yonemoto, Y., Yamada, H., Koga, N., Oguri, K., Saeki, S., 1987. Metabolism *in*  
 493 *vivo* of 3,4,3',4'-tetrachlorobiphenyl and toxicological assessment of the metabolites in rats.  
 494 Xenobiotica 17, 897–910. <https://doi.org/10.3109/00498258709044189>.